Drug Approval | June 12, 2025
Zydus receives EIR for the API manufacturing facility at Ankleshwar and Dabhasa
Zydus receives EIR for the API manufacturing facility at Ankleshwar
Zydus receives EIR for the API manufacturing facility at Ankleshwar
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Oxcarbazepine ER Tablets (RLD Oxtellar XR) had estimated annual sales of US$ 206 million in the US (IQVIA MAT April 2025)
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
The CDMO upgrade represents a transformational step for Remedium Lifecare
This outcome reflects Innoxel Lifesciences' ongoing commitment to maintaining the highest standards of quality, compliance, and regulatory excellence
Over the last 24 years, the company's sales has grown from Rs. 478 crores to Rs. 19,022 crores
These observations are procedural in nature and none of them are related to data integrity
The FDA issued Form 483 with one observation related to building and facility management
Subscribe To Our Newsletter & Stay Updated
